<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002831</url>
  </required_header>
  <id_info>
    <org_study_id>DM94-064</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-94064</secondary_id>
    <secondary_id>NCI-G96-0999</secondary_id>
    <secondary_id>CDR0000065033</secondary_id>
    <nct_id>NCT00002831</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia</brief_title>
  <official_title>A Phase I/II Study of High-Dose Deoxyazacytidine, Busulfan, and Cyclophosphamide With Allogeneic Stem Cell Transplantation for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation
      may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

      PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus
      peripheral stem cell transplantation in treating patients with chronic myelogenous or acute
      leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of decitabine in combination with
      busulfan and cyclophosphamide in patients with hematologic malignancies. II. Establish the
      pharmacokinetics of decitabine and busulfan in this patient population. III. Determine the
      effectiveness of this combination in achieving durable complete remission in patients with
      chronic myelogenous leukemia (CML) in blast crisis or acute myelogenous leukemia (AML) in
      relapse undergoing allogeneic stem cell transplantation.

      OUTLINE: In cohorts of 3, patients receive escalating doses of decitabine (DAC) IV over 4
      hours on days -8 and -7. Busulfan is administered orally every 6 hours on consecutive days -6
      through -4. Cyclophosphamide is given by vein (IV) over 1 hour on consecutive days -3 and -2.
      The maximum tolerated dose of DAC is defined as the dose at which 2 patients experience dose
      limiting toxicity. Donors receive filgrastim subcutaneously (SQ) daily every 12 hours
      starting 2-4 days prior to the first stem cell collection and before DAC infusion.
      Leukapheresis is conducted daily. If insufficient number of cells are collected, blood marrow
      is harvested for supplementation. Stem cells are infused on day 0. For graft vs host disease
      prophylaxis (GVHD), patients receive tacrolimus IV beginning one day before stem cell
      infusion, then orally following tolerance to tacrolimus. Patients intolerant to tacrolimus
      receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.
      All patients receive methylprednisolone given according to clinical grade of GVHD procedures.
      For CNS prophylaxis, methotrexate is given intrathecally or intraventricularly monthly,
      beginning on the second month through the eighth month of treatment. Allogeneic patients are
      followed until the end of 1 year.

      PROJECTED ACCRUAL: An estimated 30 allogeneic recipients will be recruited in 2 years for the
      expected study duration of 2-3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1994</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Study Duration 3 Years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Deoxyazacytidine + Busulfan + Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deoxyazacytidine + Busulfan + Cyclophosphamide With Allogeneic Stem Cell Transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to the first stem cell collection and before DAC infusion.</description>
    <arm_group_label>Deoxyazacytidine + Busulfan + Cyclophosphamide</arm_group_label>
    <other_name>C-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Administered orally every 6 hours on consecutive days -6 through -4.</description>
    <arm_group_label>Deoxyazacytidine + Busulfan + Cyclophosphamide</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given intravenously (IV) over 1 hour on consecutive days -3 and -2.</description>
    <arm_group_label>Deoxyazacytidine + Busulfan + Cyclophosphamide</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Patients intolerant to tacrolimus receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.</description>
    <arm_group_label>Deoxyazacytidine + Busulfan + Cyclophosphamide</arm_group_label>
    <other_name>Sandimmune</other_name>
    <other_name>CYA</other_name>
    <other_name>Cyclosporin A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine (DAC)</intervention_name>
    <description>IV over 4 hours on days -8 and -7.</description>
    <arm_group_label>Deoxyazacytidine + Busulfan + Cyclophosphamide</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.</description>
    <arm_group_label>Deoxyazacytidine + Busulfan + Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Given according to clinical grade of GVHD procedures.</description>
    <arm_group_label>Deoxyazacytidine + Busulfan + Cyclophosphamide</arm_group_label>
    <other_name>Depo-Medrol</other_name>
    <other_name>Medrol</other_name>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>IV beginning one day before stem cell infusion, then orally following tolerance to tacrolimus.</description>
    <arm_group_label>Deoxyazacytidine + Busulfan + Cyclophosphamide</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Infusion of stem cells on Day 0.</description>
    <arm_group_label>Deoxyazacytidine + Busulfan + Cyclophosphamide</arm_group_label>
    <other_name>ABMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Stem cell infusion on Day 0.</description>
    <arm_group_label>Deoxyazacytidine + Busulfan + Cyclophosphamide</arm_group_label>
    <other_name>PBSCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Acute leukemia past first remission or induction failure Chronic
        myelogenous leukemia in accelerated phase or blast crisis

        PATIENT CHARACTERISTICS: Age: 15 to 55 Performance status: Zubrod 0-2 Life expectancy: Life
        expectancy not severely limited by concurrent illness Hematopoietic: Not specified Hepatic:
        No evidence of chronic active hepatitis or cirrhosis Bilirubin no greater than 2 times
        upper limit of normal SGPT no greater than 4 times upper limit of normal Renal: Creatinine
        no greater than 1.5 mg/dL Cardiovascular: Left ventricular ejection fraction at least 50%
        No uncontrolled arrhythmias or symptomatic cardiac disease Pulmonary: FEV1, FVC, and DLCO
        at least 50% No symptomatic pulmonary disease Other: Related donor who is HLA-identical
        required No effusion or ascites greater than 1 L prior to drainage HIV negative Not
        pregnant No active CNS disease

        PRIOR CONCURRENT THERAPY: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Giralt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2004</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

